Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Neuro Immunoassay Market Size And Revenue Outlook Through 2030
The neuro immunoassay (NIA) market has shown robust expansion in recent years. It is anticipated to increase from $2.88 billion in 2025 to $3.12 billion in 2026, at a compound annual growth rate (CAGR) of 8.5%. This historical growth can be attributed to several factors, including the increasing demand for sensitive neurological diagnostics, the greater adoption of immunoassay techniques in neuroscience research, the rising prevalence of neurodegenerative disorders, the expansion of clinical and research laboratories, and a growing focus on early disease detection and monitoring.
The market for neuro immunoassay (NIA) products is anticipated to experience robust expansion over the coming years. It will grow to $4.28 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. This expansion during the projected timeframe stems from several factors, including the greater integration of neuro immunoassay (NIA) with artificial intelligence (AI) for data analysis, increased capital allocation towards discovering biomarkers, the wider acceptance of personalized medicine and treatment monitoring, the growth of high-throughput screening technologies, and an uptick in the need for automated and accurate immunoassay setups. Key developments anticipated in this period encompass technological breakthroughs enhancing assay sensitivity and specificity, progress in artificial intelligence (AI) for interpreting data, the evolution of multiplexed and lab-on-a-chip immunoassay systems, intensified research and development efforts in identifying neuro biomarkers, and novel approaches in integrated and automated neurodiagnostic platforms.
Get A Free Sample Report With In-Depth Market Insights:
Neuro Immunoassay Market Industry Drivers: What’s Behind The Revenue Growth?
A surge in neurological disorder cases is anticipated to drive the expansion of the neuro immunoassay market in the future. These conditions involve medical ailments impacting the brain, spinal cord, and nerves, thus interfering with typical nervous system operations and resulting in deficiencies in movement, thought processes, perception, conduct, or general bodily regulation. The rising incidence of neurological disorders stems from detrimental lifestyle practices such as inadequate nutrition, lack of physical activity, tobacco use, high alcohol intake, and persistent stress. Neuro immunoassays facilitate the identification of particular biomarkers within the nervous system, thereby aiding in the prompt diagnosis and tailored therapeutic approaches for individuals with neurological conditions. For example, in April 2024, data from the National Institutes of Health (NIH), a US government entity, indicated that approximately 6.9 million Americans aged 65 and above are presently suffering from Alzheimer’s dementia, with projections showing this number will almost double to 13.8 million by 2060. Consequently, the growing occurrence of neurological disorders is a significant force behind the neuro immunoassay market.
Neuro Immunoassay Market Segment Landscape: Which Areas Lead Development?
The neuro immunoassay market covered in this report is segmented –
1) By Product Type: Reagents And Kits, Analyzers
2) By Technology: Radioimmunoassays (RIA), Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), Western Blot, Rapid Tests, Enzyme-Linked Immunospot Assay (ELISPOT)
3) By Analyte Or Biomarker Type: Amyloid-Beta (Aß), Tau Protein (p-Tau), Alpha-Synuclein (a-syn), Neurofilament Light Chain (NfL), Autoantibodies, Cytokines, Glial Fibrillary Acidic Protein (GFAP), Neuron-Specific Enolase (NSE), Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), Brain-Derived Neurotrophic Factor (BDNF)
4) By Application: Alzheimer’s Disease, Parkinson’s Disease (PD), Huntington’s Disease, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy (SMA)
5) By End-User: Hospitals, Clinics, Academic Organizations, Biopharmaceutical Companies, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Reagents And Kits: Enzyme Linked Immunosorbent Assay Reagents, Western Blotting Kits, Multiplex Assay Kits
2) By Analyzers: Automated Immunoassay Analysers, Point Of Care Immunoassay Analysers, High Throughput Immunoassay Analysers
#Neuro Immunoassay Market Growth Trends: What’s Shaping The Future Outlook?
Major companies in the neuro immunoassay market are prioritizing the development of advanced solutions, such as blood-based neurological biomarker assays. These innovations aim to enhance disease monitoring, improve the accuracy of prognoses, and support clinical decision-making for neurological disorders. Blood-based neurological biomarker assays are tests designed to measure specific proteins, like Neurofilament Light Chain (NfL), in human serum or plasma to evaluate neuronal injury and disease activity. For instance, in June 2024, Siemens Healthineers, a Germany-based in vitro diagnostics company, secured CE marking for its Neurofilament Light Chain blood test. This test is engineered for compatibility with the Atellica IM Analyzer and ADVIA Centaur systems. The test quantifies NfL levels to assist in predicting neuronal injury risk in adults with relapsing multiple sclerosis, serving as a complement to clinical, imaging, and laboratory assessments. The CE mark confirms compliance with European In Vitro Diagnostic Regulations, thereby expanding access to standardized neuro immunoassay diagnostics across European laboratories.
Neuro Immunoassay Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the neuro immunoassay market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories Inc., GenScript Biotech Corporation, Abcam plc, BioLegend Inc., Meso Scale Diagnostics LLC, Sino Biological Inc., Quanterix Corporation, Cusabio Technology LLC, OriGene Technologies Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., Assay Genie Ltd., Novus Biologicals LLC, Creative Diagnostics, MyBioSource Inc., Immuno-Biological Laboratories Co. Ltd., Boster Biological Technology, Cloud-Clone Corp., FineTest Biotech Inc., Abbexa Ltd.
View The Full Neuro Immunoassay Market Report:
Neuro Immunoassay Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the neuro immunoassay (NIA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuro immunoassay market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
